{"disease":{"id":"peptide-receptor-radionuclide-therapy","name":"peptide receptor radionuclide therapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05427032","title":"HRQoL During PRRT in Patients With NETs","phase":"","overall_status":"COMPLETED","enrollment_count":756,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT04790708","title":"Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"University Hospital of Ferrara","has_results":false},{"nct_id":"NCT06121271","title":"Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":110,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT05870423","title":"Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Erasmus Medical Center","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}